Has Chaundre Cross received payments from drug or device companies?

Yes. Drug and device makers reported $131,131 in general payments to Chaundre Cross across 227 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chaundre Cross did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chaundre Cross come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chaundre Cross

Radiation Oncology · Naples, FLNPI 1972506707

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $96,860 of the $131,131 with a category attached, or 73.9%. Johnson & Johnson accounts for 67.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $59,587 and has fallen 78.0% since, to $13,101 in 2022. Among radiation oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$131,131in general payments, 2019–2025

Across 227 payments — averaging $577.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$88K
Astellas Pharma US Inc$19K
Pfizer$14K
Bayer$4K
Novocure Inc.$3K
AstraZeneca$2K
plus $1K from 15 others

What the payments were for

Consulting fees$19,69515%
Speaking & faculty fees$96,86074%
Travel & lodging$9,9998%
Food & beverage$4,4903%
Education$880%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	117	$88,133
Astellas Pharma US Inc	28	$19,084
Pfizer	21	$13,904
Bayer	9	$3,521
Novocure Inc.	7	$2,790
AstraZeneca	2	$2,225
Dendreon Pharmaceuticals LLC	8	$190
Regeneron Healthcare Solutions, Inc.	6	$183
Boston Scientific	3	$179
Foundation Medicine, Inc.	5	$178
Sirtex Medical Inc	2	$159
Blue Earth Diagnostics	5	$136
Sanofi	1	$125
Eisai Inc.	1	$110
Tolmar Pharmaceuticals, Inc.	3	$54
Sun Pharmaceutical Industries Inc.	2	$42
Palette Life Sciences, Inc.	2	$39
Myovant Sciences Inc.	2	$30
Monteris Medical Corporation	1	$24
Myriad Genetic Laboratories, Inc.	1	$13
Amgen	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,131 in reported general payments places this provider in the 95th percentile of 465 radiation oncology providers in Florida.

See all radiation oncology providers in Florida →

Other radiation oncology in Naples

Timothy KerwinNaples$65K
Kristina Mirabeau-BealeNaples$16K
Shravan KandulaOrlando$444K
Martin KeischMiami Shores$319K
Marcio FagundesMiami$274K
Evan ThomasWinter Park$209K
Rupesh KotechaMiami$208K
John SylvesterLakewood Ranch$205K
Ravi ShridharOrlando$192K
Alan BrownFort Myers$165K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →